Needham Reiterates a Hold Rating on Avadel Pharmaceuticals (AVDL)

​The standing follows the company’s Q3 2025 results released connected November 4. During the quarter, the institution grew its gross by 54.86% year-over-year to $77.47 million, surpassing analysts’ estimates by $3.89 million. However, the EPS of $0 fell abbreviated of the expectations by $0.05. Management attributed gross maturation to robust income of LUMRYZ and a 48% summation to 3,400 patients connected LUMRYZ arsenic of September 30, 2025.

​Although Avadel Pharmaceuticals plc (NASDAQ:AVDL) missed EPS estimates, its nett income of $20,000 for the 4th was significant. The nett income reflected a important betterment versus the aforesaid 4th erstwhile year, wherever the institution reported a nett nonaccomplishment of $2.6 million, translating to a antagonistic EPS of $0.03. This was aided by a reversal of $9.5 cardinal by Jazz successful conjunction with the Settlement Agreement.

​Avadel Pharmaceuticals plc (NASDAQ:AVDL) is simply a biopharmaceutical institution that develops extended-release cause formulations to amended diligent attraction experiences. Their main product, LUMRYZ, is an FDA-approved once-at-bedtime extended-release sodium oxybate therapy for excessive daytime sleepiness successful adults and children with narcolepsy.

While we admit the imaginable of AVDL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.